Mary Gleeson

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Sandy Amorim, Anastasios Stathis, Mary Gleeson et al. · The Lancet Haematology · 2016 · 428 citations

Medicine, Pharmacokinetics, Pharmacology +13

Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial

Mary Gleeson, Nicholas Counsell, David Cunningham et al. · Annals of Oncology · 2017 · 90 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

The effects of carbohydrate supplementation on immune responses to a soccer-specific exercise protocol

Nicolette C. Bishop, Andrew K. Blannin, Paula J. Robson et al. · Journal of Sports Sciences · 1999 · 85 citations

Life Sciences, Kinesiology, Physiology +10

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial

Mary Gleeson, Clare Peckitt, Ye To et al. · The Lancet Haematology · 2018 · 71 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London

Beth Russell, Charlotte Moss, Sophie Papa et al. · Frontiers in Oncology · 2020 · 64 citations · Full text

Medicine, Oncology, Cancer Epidemiology +11